Source: CureToday articles
Adding Imfinzi to fluorouracil-based chemo improved event-free survival and response rates in resectable gastric and gastroesophageal junction cancer.
Recent Content
- Patient Perspective: Navigating Multiple Myeloma Treatment
- LAMP5 modulates IRF4 stability and nuclear transport: a critical mechanism in myeloma progression and therapy
- High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease
- Value of Spectral CT Techniques for the Assessment of Bone Marrow Infiltration in Multiple Myeloma: A Systematic Literature Review
- EHA 2025: Early Data Support Tocilizumab Use to Enable Outpatient Talquetamab Dosing in R/R Multiple Myeloma
- VIDEO: Four drugs ‘appear to be better’ in treatment of newly diagnosed multiple myeloma
- VIDEO: Cilta-cel may offer ‘cure’ in relapsed, refractory multiple myeloma
- Treatment-related cognitive changes in multiple myeloma: A systematic review and meta-analysis
- NCCN Flash Update: Linvoseltamab Added as Preferred Regimen After 4 Prior Therapies for Multiple Myeloma
- FDA Panel Rejects Belantamab Mafodotin Combinations for Multiple Myeloma, Citing Safety Concerns